ccr5  (Bioss)

Journal: The Journal of Biological Chemistry

Article Title: Androgen receptor–induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p–CCR5 axis

doi: 10.1016/j.jbc.2025.108428

Figure Lengend Snippet: SOX2-OT promotes CCR5 expression via miR-320a-5p. A , putative miR-320a-5p binding site and mutant sequences in the 3′UTR of CCR5. B , luciferase activity of CCR5 WT and CCR5 MUT upon transfection of miR-320a-5p mimics in 293T cells. ∗∗∗ p < 0.001 by t test. C , CCR5 mRNA level of MDA-MB-231 and Hs578t transfected with miR-320a-5p mimic or inhibitor. ∗∗ p < 0.01, ∗∗∗ p < 0.001 by t test. D and E , CCR5 mRNA level of MDA-MB-231 and Hs578t transfected with SOX2-OT WT, SOX2-OT MUT, or shSOX2-OT, and miR-320a-5p mimic or inhibitor. ∗∗ p < 0.01, ∗∗∗ p < 0.001 by t test. F , relative protein levels of MDA-MB-231 and Hs578t transfected with SOX2-OT WT, SOX2-OT MUT, or shSOX2-OT, and miR-320a-5p mimic or inhibitor. G and H , cell growth inhibition rate of MDA-MB-231 and Hs578t cells transfected with SOX2-OT WT, SOX2-OT MUT, or shSOX2-OT, and miR-320a-5p mimic or inhibitor. I and J , cell apoptosis assay of MDA-MB-231 and Hs578t cells transfected with SOX2-OT WT, SOX2-OT MUT, or shSOX2-OT, and miR-320a-5p mimic or inhibitor. ∗∗ p < 0.01, ∗∗∗ p < 0.001 by t test. Results represented the average of three independent experiments, and the data represent the mean ± SD.

Article Snippet: Antibodies used for IHC were anti-AR antibody (ab198394; Abcam), anti-CCR5 antibody (bs2514R; Bioss), and anti-Ki-67 antibody (ab16667; Abcam).

Techniques: Expressing, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Transfection, Inhibition, Apoptosis Assay

Journal: The Journal of Biological Chemistry

Article Title: Androgen receptor–induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p–CCR5 axis

doi: 10.1016/j.jbc.2025.108428

Figure Lengend Snippet: SOX2-OT–CCR5 axis promotes TNBC tumorigenesis in vivo . A , representative photographs of xenograft tumors were taken 3 weeks after injection. B , tumor sizes were measured at the indicated time points. ∗ p < 0.05, ∗∗∗ p < 0.001 by t test. C , excised tumors were weighed. ∗∗ p < 0.01, ∗∗∗ p < 0.001 by t test. D , relative mRNA expression levels of the excised xenografts. ∗∗ p < 0.01, ∗∗∗ p < 0.001 by t test. E , relative protein expression levels of the excised xenografts. F , representative IHC staining in the tissue from the excised xenografts. The scale bar represents 20 μm. ∗∗ p < 0.01, ∗∗∗ p < 0.001 by t test. Results represented the average of three independent experiments, and the data represent the mean ± SD. IHC, immunohistochemistry; TNBC, triple-negative breast cancer.

Article Snippet: Antibodies used for IHC were anti-AR antibody (ab198394; Abcam), anti-CCR5 antibody (bs2514R; Bioss), and anti-Ki-67 antibody (ab16667; Abcam).

Techniques: In Vivo, Injection, Expressing, Immunohistochemistry

Journal: The Journal of Biological Chemistry

Article Title: Androgen receptor–induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p–CCR5 axis

doi: 10.1016/j.jbc.2025.108428

Figure Lengend Snippet: The expression of AR–SOX2-OT–miR-320a-5p–CCR5 axis in TNBC patients. A , representative IHC or ISH staining of AR, SOX2-OT, miR-320a-5p, and CCR5 in the same tissue from patients with TNBC. The scale bar represents 20 μm (50 μm for enlarged diagram). B , correlation of AR, SOX2-OT, miR-320a-5p, and CCR5 expression in tissue from 165 patients with TNBC. p Values are calculated by Pearson correlation analysis. C , a schematic model of AR–SOX2-OT–miR-320a-5p–CCR5 signaling in the TNBC tumorigenesis. AR promotes SOX2-OT expression. In patients with a low AR expression, SOX2-OT blinds to miR-320a-5p, and the expression level of SOX2-OT is also low. In patients with a high AR expression, SOX2-OT acts as a molecular sponge for miR-320a-5p, leading to activating CCR5 signaling pathway and promoting TNBC tumorigenesis. AR, androgen receptor; IHC, immunohistochemistry; ISH, in situ hyridization; TNBC, triple-negative breast cancer.

Article Snippet: Antibodies used for IHC were anti-AR antibody (ab198394; Abcam), anti-CCR5 antibody (bs2514R; Bioss), and anti-Ki-67 antibody (ab16667; Abcam).

Techniques: Expressing, Staining, Immunohistochemistry, In Situ

Journal: PLoS ONE

Article Title: The enhancement of CCL2 and CCL5 by human bone marrow-derived mesenchymal stem/stromal cells might contribute to inflammatory suppression and axonal extension after spinal cord injury

doi: 10.1371/journal.pone.0230080

Figure Lengend Snippet: Primary antibodies used for immunohistochemistry.

Article Snippet: CCR5 , Rabbit , Bioss (Boston, MA) , bs-2514R , 500.

Techniques: Immunohistochemistry